Verdict: Side-by-side breakdown using the Bull Rankings model. NBIX scored 87.2, ANIP scored 82.7 — NBIX leads.
Compare another set
NBIX
Neurocrine Biosciences, Inc.
Drug Manufacturers - Specialty & Generic · Quality-Growth
87.2
$142.44 · $14.5B
fundamentals as of
Score gap
4.5
NBIX leads
ANIP
ANI Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic · Quality-Growth
82.7
$73.89 · $1.7B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
CheapestANIP16.0x
Fastest growthANIP+43.8%
Strongest balance sheetNBIX0.12
Highest qualityNBIX80 / 100
Largest discount to fair valueANIP-56%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
NBIX
stronger →← stronger
ANIP
80
Qualityreturns · margins · balance sheet
66
96
Growthrevenue & earnings expansion
93
86
Valuevaluation vs sector peers
92
NBIX is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
NBIX
ANIP
$870mC+
FCF
$168mC
+34.4%A
Rev
+43.8%A
0.12B+
D/E
1.05C
20.9xB+
P/E
16.0xA-
0.28A
PEG
1.78C+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
NBIX
ANIP
24% below
Price vs fair valuelower is cheaper
56% below
~7%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~-5%/yr
+5%
1-yr DCF upside
+76%
+32%
5-yr DCF upside
+129%
+85%
10-yr DCF upside
+237%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Drug Manufacturers - Specialty & Generic · market cap $14.5b. Down 23% from 52-week high of $186.12 — deep drawdown territory. Revenue growing +34% — in hypergrowth territory. PEG 0.28 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $207.29 (implying +46% upside).
Moat
Net margin 21% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 19% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 123% of net income — earnings translate cleanly into cash.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Drug Manufacturers - Specialty & Generic · market cap $1.7b. Down 24% from 52-week high of $97.00 — deep drawdown territory. Revenue growing +44% — in hypergrowth territory. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $105.78 (implying +43% upside).
Moat
ROE 20% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 168% of net income — earnings translate cleanly into cash. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
The model favors NBIX (87.5) over ANIP (85.4) primarily due to NBIX's superior Quality pillar score of 81, reflecting its durable high returns. However, a contrarian might prefer ANIP, which trades at a significant 46% discount to our DCF fair value and implies a negative 6% growth rate, indicating less optimism is priced in. NBIX also carries a "Diluting shareholders" signal, a caution for investors.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where NBIX and ANIP diverge
On the headline score the gap is 4.5 points in favor of NBIX. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
QualityNBIX 80.5 · ANIP 66.4NBIX +14.1
ValueNBIX 86.0 · ANIP 92.0ANIP +6.0
GrowthNBIX 95.9 · ANIP 92.6NBIX +3.3
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is NBIX or ANIP the better stock?
NBIX scores higher: NBIX 87.2, ANIP 82.7 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do NBIX and ANIP differ most?
The widest gap is quality, where NBIX leads by 14 points on the 0–100 pillar scale. Neither name sweeps: they trade the lead across the three pillars, so the comparison is a trade-off rather than one being better on every measure.
How are NBIX and ANIP scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.